A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical study to evaluate the efficacy of Chinese medicine powder in reliving patients with chronic gastritis from gastralgia and gastrect

Study of prevention and treatment of Traditional Chinese Medicine of chronic gastritis and application of standard

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10001360

Enrollment

Unknown

Registered

2010-12-14

Start date

2011-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Gastritis

Interventions

Group B:Chinese medicine powder dummy 4.5g in one bag

Group A:Chinese medicine powder 4.5g in one bag

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria of chronic gastritis; 2. Age limited between 18 and 70 years old; 3. Times of gastralgia (or gastrectasia) attacking are more than 2 days in one week within recently a month; 4. Informed consent and will accept the corresponding treatment.

Exclusion criteria

Exclusion criteria: 1. Patients with chronic atrophic gastritis with severe hyperplasia, upper gastrointestinal bleeding, peptic ulcer and gastrointestinal tumors; 2. Patients with organic diseases of digestive system (such as chronic pancreatitis, liver cirrhosis, etc), or systemic diseases influencing gastrointestinal power (e.g. hyperthyroidism, diabetes, chronic renal insufficiency, mental and neurological, etc); 3. Patients accompany with serious lesion of heart, kidney, liver and other main organ, hematopoietic system diseases and tumor.(Notice to identify angina pectoris.); 4. Take drugs affecting the gastrointestinal function continuous within a week. (such as H2RA, PPI, gastric mucosal protective drugs, anti-acid drugs, gastrointestinal agent drugs and so on ); 5. Pregnant or lactating females; 6. History of psychiatric or nervous system disease; 7. Patients allergic to the drugs; 8. Patients taking part in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Remission rates of gastralgia and gastrectasia at 30min after taking medicine.;	—

Secondary

Measure	Time frame
Times of gastralgia and gastrectasia attacking within research course;Degrees of alleviating symptoms at time when symptoms first attacking, 0.5, 1, 1.5, 2 hours after ta;Medication within research cours;	—

Countries

China

Contacts

Public ContactXudong Tang

txdly@sina.com+86 13901137632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026